查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1871894

非药物调变器市场预测至2032年：按作用方式、作用机制、供应类型、分销管道、应用、最终用户和地区分類的全球分析

Non-Pharmacologic Modulators Market Forecasts to 2032 - Global Analysis By Modality, Mechanism of Action, Delivery Mode, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预计到 2025 年，全球非药物调变器市场规模将达到 17.8 亿美元，到 2032 年将达到 25.5 亿美元，预测期内复合年增长率为 5.2%。

非药物调变器是指无需使用药物即可影响生理或心理过程的治疗性介入。这些方法包括认知行为疗法、神经调控、物理復健、正念疗法和生活方式调整。它们常用于疼痛管理、心理健康和慢性病护理，旨在透过增强人体自身的调节机制来优化患者的治疗效果。非药物调变器因其副作用小、疗效持久以及能够补充或减少对药物治疗的依赖性而备受青睐。

人们越来越倾向于选择非侵入性治疗

由于副作用较少且患者依从性更高，神经调控、认知行为疗法 (CBT) 和生物回馈疗法等疗法正受到患者和医疗专业人员的青睐。这些治疗方法能够针对性地缓解症状，并且避免了药物相关的全身性风险。此外，穿戴式科技和数位平台的进步也使得这些疗法更加普及和个人化。

缺乏长期疗效数据

许多治疗方法缺乏标准化的临床通讯协定，导致难以比较不同族群和疾病的治疗效果。这种循证数据的缺乏会阻碍监管部门的核准和报销，从而减缓市场渗透。此外，传统医疗机构的质疑态度也会限制这些疗法融入主流治疗体系。如果没有强有力的临床试验和上市后监测，这些治疗方法的扩充性和可靠性仍然有限。

老化社会与神经退化性疾病护理

阿兹海默症、帕金森氏症和轻度认知障碍等疾病推动了对无需药物负担即可支持神经可塑性和自主神经调节的治疗方法的需求。脑机介面、引导式神经回馈和居家认知训练工具等创新技术正在拓展老年护理的治疗选择。此外，医疗保健系统正在投资于旨在降低多重用药风险和提高老年人生活品质的非药物干预措施，这为市场扩张创造了有利条件。

来自药物和混合疗法的竞争

生物製药、标靶治疗和联合疗法因其快速缓解症状和较高的临床接受度，往往分散人们对其他疗法的关注。此外，製药公司受益于成熟的分销网络和报销体系，使得非药物疗法难以获得同等的市场份额。随着混合模式将数位疗法与药物疗法结合，独立调节剂必须透过疗效、成本效益和病人参与来脱颖而出，保持其市场地位。

新冠疫情的影响：

新冠疫情加速了人们对远端医疗和非侵入性医疗解决方案的兴趣，为非药物调变器市场带来了利好。封锁措施和医疗机构的紧张状况促使患者寻求居家治疗，以缓解压力、疼痛和神经系统疾病。随着人们更加重视在临床环境之外维护心理健康和管理慢性疾病，数位认知行为疗法（CBT）平台、穿戴式神经调节设备和支持远端医疗的生物回馈疗法工具的使用率显着提高。然而，供应链中断和临床试验的延迟暂时阻碍了产品开发和监管核准。

预计在预测期内，认知行为疗法（CBT）细分市场将占据最大的市场份额。

由于认知行为疗法 (CBT) 应用广泛，涵盖心理健康、疼痛管理和行为障碍等领域，预计在预测期内，CBT 将占据最大的市场份额。 CBT 易于适应数位化平台，且以实证医学为基础，因此深受临床医生和患者的青睐。该领域受益于人们对心理健康的日益关注、数位疗法资金的增加以及数位疗法在基层医疗机构中的应用。 CBT 的模组化设计使其能够制定个人化的治疗方案，从而提高其在不同患者群体中的有效性和扩充性。

预计在预测期内，自主神经调节领域将呈现最高的复合年增长率。

预计在预测期内，自主神经系统调节领域将达到最高成长率，这主要得益于其在压力相关疾病、心血管健康和神经退化性疾病管理中的重要角色。迷走神经刺激、心率变异性训练和引导式呼吸等技术因其恢復生理平衡的能力而备受关注。穿戴式生物感测器和人工智慧驱动的回馈系统的创新也为该领域提供了支持，这些创新能够实现即时监测和自适应治疗。

占比最大的地区：

由于北美拥有完善的医疗保健基础设施、对非药物疗法的高度认知以及有利的报销政策，预计该地区将在预测期内占据最大的市场份额。该地区汇聚了许多数位疗法和神经调控领域的主要企业，推动创新和早期应用。政府促进心理健康和慢性病管理的措施也进一步刺激了市场需求。此外，将非药物调变器整合到远端医疗平台和企业健康计画中，正在扩大其在都市区和农村地区的覆盖范围。

复合年增长率最高的地区：

在预测期内，北美预计将实现最高的复合年增长率，这主要得益于对研究、技术和医疗数位化的持续投资。该地区在心理健康、老年护理和预防医学方面采取的积极主动的态度，为非侵入性治疗方法创造了有利条件。学术机构、Start-Ups和医疗服务提供者之间的合作正在加速产品开发和临床检验。在消费者对个人化和整体护理需求不断增长的推动下，北美仍然是市场扩张的活力中心。

关于免费客製化服务：

购买此报告的客户可享有以下免费自订选项之一：

  • 公司概况
    • 对其他市场参与者（最多 3 家公司）进行全面分析
    • 主要参与者（最多3家公司）的SWOT分析
  • 区域细分
    • 根据客户兴趣对主要国家进行市场估算、预测和复合年增长率分析（註：基于可行性检查）
  • 竞争基准化分析
    • 根据主要参与者的产品系列、地理覆盖范围和策略联盟基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 原始研究资料
    • 次级研究资讯来源
    • 先决条件

第三章 市场趋势分析

  • 介绍
  • 司机
  • 抑制因素
  • 机会
  • 威胁
  • 应用分析
  • 终端用户分析
  • 新兴市场
  • 新冠疫情的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球非药物调变器市场（依治疗方式划分）

  • 介绍
  • 认知行为治疗（CBT）
  • 正念减压疗法（MBSR）
  • 生物回馈疗法
  • 神经回馈
  • 经颅磁刺激（TMS）
  • 其他方式

6. 全球非药物调变器市场依作用机制划分

  • 介绍
  • 增强的神经可塑性
  • 自主神经系统的调节
  • 荷尔蒙调节
  • 免疫系统调节
  • 阻断疼痛通路
  • 其他机制

7. 全球非药物调变器市场（依供应类型划分）

  • 介绍
  • 面对面治疗
  • 数位疗法
  • 穿戴式装置
  • 远端监控平台
  • 其他供应形式

8. 全球非药物调变器市场（依分销管道划分）

  • 介绍
  • 直销
  • 经销商
  • 线上平台
  • 其他频道

9. 全球非药物调变器市场（按应用划分）

  • 介绍
  • 慢性疼痛管理
  • 精神疾病
  • 神经復健
  • 睡眠障碍
  • 心血管调节
  • 其他应用

10. 全球非药物调变器市场（依最终用户划分）

  • 介绍
  • 医院
  • 专科诊所
  • 復健中心
  • 居家照护机构
  • 学术研究机构
  • 其他最终用户

11. 全球非药物调变器市场（按地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 亚太其他地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲国家
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与併购
  • 新产品上市
  • 业务拓展
  • 其他关键策略

第十三章：企业概况

  • Neuroelectrics
  • Flow Neuroscience
  • Happify Health
  • Pear Therapeutics
  • Fisher Wallace Laboratories
  • NeuroSky
  • MindMaze
  • Omada Health
  • Better Therapeutics
  • BehaVR
  • Neurovalens
  • NeuroSigma
  • Cognifisense
  • NeuroTherapeutics Pharma
  • NeuroMetrix
  • Theranica
Product Code: SMRC32264

According to Stratistics MRC, the Global Non-Pharmacologic Modulators Market is accounted for $1.78 billion in 2025 and is expected to reach $2.55 billion by 2032 growing at a CAGR of 5.2% during the forecast period. Non-pharmacologic modulators are therapeutic interventions that influence physiological or psychological processes without the use of pharmaceutical agents. These approaches include techniques such as cognitive-behavioral therapy, neuromodulation, physical rehabilitation, mindfulness, and lifestyle modifications. Often employed in pain management, mental health, and chronic disease care, they aim to optimize patient outcomes by enhancing the body's natural regulatory mechanisms. Non-pharmacologic modulators are valued for their minimal side effects, long-term benefits, and ability to complement or reduce reliance on medication-based treatments.

Market Dynamics:

Driver:

Growing preference for non-invasive treatments

Patients and clinicians alike are gravitating toward therapies such as neuromodulation, cognitive behavioral therapy (CBT), and biofeedback due to their reduced side-effect profiles and improved patient compliance. These modalities offer targeted symptom relief without the systemic risks associated with pharmaceuticals. Moreover, advancements in wearable technologies and digital platforms are enhancing the accessibility and personalization of these treatments.

Restraint:

Limited long-term efficacy data

Many interventions lack standardized clinical protocols, making it difficult to compare outcomes across populations and conditions. This gap in evidence-based data can hinder regulatory approvals and payer reimbursement, slowing market penetration. Additionally, skepticism among traditional healthcare providers may limit integration into mainstream treatment pathways. Without robust clinical trials and post-market surveillance, scalability and trust in these modalities remain constrained.

Opportunity:

Aging population and neurodegenerative care

Conditions such as Alzheimer's, Parkinson's, and mild cognitive impairment are driving demand for therapies that support neuroplasticity and autonomic regulation without pharmacologic burden. Innovations in brain-computer interfaces, guided neurofeedback, and home-based cognitive training tools are expanding therapeutic options for geriatric care. Furthermore, healthcare systems are investing in non-drug interventions to reduce polypharmacy risks and improve quality of life among older adults, creating fertile ground for market expansion.

Threat:

Competition from pharmacologic and hybrid therapies

Biologics, targeted therapies, and combination approaches often offer faster symptom relief or broader clinical acceptance, drawing attention away from alternative modalities. Additionally, pharmaceutical companies benefit from established distribution networks and reimbursement frameworks, making it harder for non-drug solutions to gain comparable traction. As hybrid models integrate digital therapeutics with pharmacologic regimens, standalone modulators must differentiate through efficacy, cost-effectiveness, and patient engagement to maintain relevance.

Covid-19 Impact:

The COVID-19 pandemic accelerated interest in remote and non-invasive healthcare solutions, benefiting the non-pharmacologic modulators market. Lockdowns and overwhelmed healthcare facilities prompted patients to seek home-based therapies for stress, pain, and neurological conditions. Digital CBT platforms, wearable neuromodulators, and telehealth-enabled biofeedback tools saw increased adoption as individuals prioritized mental well-being and chronic disease management outside clinical settings. However, supply chain disruptions and delayed clinical trials temporarily hindered product development and regulatory approvals.

The cognitive behavioral therapy (CBT) segment is expected to be the largest during the forecast period

The cognitive behavioral therapy (CBT) segment is expected to account for the largest market share during the forecast period due to its widespread application across mental health, pain management, and behavioral disorders. CBT's adaptability to digital platforms and its evidence-based framework make it a preferred choice among clinicians and patients. The segment benefits from growing awareness of mental health, increased funding for digital therapeutics, and integration into primary care settings. CBT's modular design allows for personalized treatment plans, enhancing its effectiveness and scalability across diverse populations.

The autonomic nervous system regulation segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the autonomic nervous system regulation segment is predicted to witness the highest growth rate driven by its role in managing stress-related disorders, cardiovascular health, and neurodegenerative conditions. Techniques such as vagus nerve stimulation, heart rate variability training, and guided breathing exercises are gaining traction for their ability to restore physiological balance. The segment is supported by innovations in wearable biosensors and AI-driven feedback systems that enable real-time monitoring and adaptive therapy.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share supported by robust healthcare infrastructure, high awareness of non-drug therapies, and favorable reimbursement policies. The region hosts several key players in digital therapeutics and neuromodulation, fostering innovation and early adoption. Government initiatives promoting mental health and chronic disease management further bolster demand. Additionally, the integration of non-pharmacologic modulators into telehealth platforms and employer wellness programs is expanding their reach across urban and rural populations.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR driven by continuous investment in research, technology, and healthcare digitization. The region's proactive stance on mental health, aging care, and preventive medicine is creating fertile ground for non-invasive therapies. Collaborations between academic institutions, startups, and healthcare providers are accelerating product development and clinical validation. As consumer demand for personalized and holistic care grows, North America remains a dynamic hub for market expansion.

Key players in the market

Some of the key players in Non-Pharmacologic Modulators Market include Neuroelectrics, Flow Neuroscience, Happify Health, Pear Therapeutics, Fisher Wallace Laboratories, NeuroSky, MindMaze, Omada Health, Better Therapeutics, BehaVR, Neurovalens, NeuroSigma, Cognifisense, NeuroTherapeutics Pharma, NeuroMetrix, and Theranica.

Key Developments:

In September 2025, NeuroMetrix shows aprivacy statement / site update and maintains an investor/SEC filings area with 2025 filings indicating corporate/IR activity in 2025. This is a site / regulatory-document update rather than a product launch, but it is a verifiable 2025 entry on the company's investor/privacy pages.

In July 2025, Neuroelectrics sponsored and promoted Workshop 7 ("The Varieties of BCI Brain Computer Interfaces") at The Science of Consciousness (TSC) Barcelona conference, highlighting academic and industry talks supported by the company.

In April 2025, Neuroelectrics announced a breakthrough in depression treatment" tied to an RCT. The announcement described the trial design (60 patients) comparing optimized multichannel tDCS, conventional tDCS and sham for major depression, positioning Neuroelectrics in clinical-trial activity in 2025.

Modalities Covered:

  • Cognitive Behavioral Therapy (CBT)
  • Mindfulness-Based Stress Reduction (MBSR)
  • Biofeedback
  • Neurofeedback
  • Transcranial Magnetic Stimulation (TMS)
  • Other Modalities

Mechanism of Actions Covered:

  • Neuroplasticity Enhancement
  • Autonomic Nervous System Regulation
  • Hormonal Modulation
  • Immune System Modulation
  • Pain Pathway Interruption
  • Other Mechanisms

Delivery Modes Covered:

  • In-Person Therapy
  • Digital Therapeutics
  • Wearable Devices
  • Remote Monitoring Platforms
  • Other Delivery Modes

Distribution Channels Covered:

  • Direct Sales
  • Distributors
  • Online Platforms
  • Other Channels

Applications Covered:

  • Chronic Pain Management
  • Mental Health Disorders
  • Neurological Rehabilitation
  • Sleep Disorders
  • Cardiovascular Regulation
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Rehabilitation Centers
  • Homecare Settings
  • Academic & Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Non-Pharmacologic Modulators Market, By Modality

  • 5.1 Introduction
  • 5.2 Cognitive Behavioral Therapy (CBT)
  • 5.3 Mindfulness-Based Stress Reduction (MBSR)
  • 5.4 Biofeedback
  • 5.5 Neurofeedback
  • 5.6 Transcranial Magnetic Stimulation (TMS)
  • 5.7 Other Modalities

6 Global Non-Pharmacologic Modulators Market, By Mechanism of Action

  • 6.1 Introduction
  • 6.2 Neuroplasticity Enhancement
  • 6.3 Autonomic Nervous System Regulation
  • 6.4 Hormonal Modulation
  • 6.5 Immune System Modulation
  • 6.6 Pain Pathway Interruption
  • 6.7 Other Mechanisms

7 Global Non-Pharmacologic Modulators Market, By Delivery Mode

  • 7.1 Introduction
  • 7.2 In-Person Therapy
  • 7.3 Digital Therapeutics
  • 7.4 Wearable Devices
  • 7.5 Remote Monitoring Platforms
  • 7.6 Other Delivery Modes

8 Global Non-Pharmacologic Modulators Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Distributors
  • 8.4 Online Platforms
  • 8.5 Other Channels

9 Global Non-Pharmacologic Modulators Market, By Application

  • 9.1 Introduction
  • 9.2 Chronic Pain Management
  • 9.3 Mental Health Disorders
  • 9.4 Neurological Rehabilitation
  • 9.5 Sleep Disorders
  • 9.6 Cardiovascular Regulation
  • 9.7 Other Applications

10 Global Non-Pharmacologic Modulators Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Rehabilitation Centers
  • 10.5 Homecare Settings
  • 10.6 Academic & Research Institutes
  • 10.7 Other End Users

11 Global Non-Pharmacologic Modulators Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Neuroelectrics
  • 13.2 Flow Neuroscience
  • 13.3 Happify Health
  • 13.4 Pear Therapeutics
  • 13.5 Fisher Wallace Laboratories
  • 13.6 NeuroSky
  • 13.7 MindMaze
  • 13.8 Omada Health
  • 13.9 Better Therapeutics
  • 13.10 BehaVR
  • 13.11 Neurovalens
  • 13.12 NeuroSigma
  • 13.13 Cognifisense
  • 13.14 NeuroTherapeutics Pharma
  • 13.15 NeuroMetrix
  • 13.16 Theranica

List of Tables

  • Table 1 Global Non-Pharmacologic Modulators Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Non-Pharmacologic Modulators Market Outlook, By Modality (2024-2032) ($MN)
  • Table 3 Global Non-Pharmacologic Modulators Market Outlook, By Cognitive Behavioral Therapy (CBT) (2024-2032) ($MN)
  • Table 4 Global Non-Pharmacologic Modulators Market Outlook, By Mindfulness-Based Stress Reduction (MBSR) (2024-2032) ($MN)
  • Table 5 Global Non-Pharmacologic Modulators Market Outlook, By Biofeedback (2024-2032) ($MN)
  • Table 6 Global Non-Pharmacologic Modulators Market Outlook, By Neurofeedback (2024-2032) ($MN)
  • Table 7 Global Non-Pharmacologic Modulators Market Outlook, By Transcranial Magnetic Stimulation (TMS) (2024-2032) ($MN)
  • Table 8 Global Non-Pharmacologic Modulators Market Outlook, By Other Modalities (2024-2032) ($MN)
  • Table 9 Global Non-Pharmacologic Modulators Market Outlook, By Mechanism of Action (2024-2032) ($MN)
  • Table 10 Global Non-Pharmacologic Modulators Market Outlook, By Neuroplasticity Enhancement (2024-2032) ($MN)
  • Table 11 Global Non-Pharmacologic Modulators Market Outlook, By Autonomic Nervous System Regulation (2024-2032) ($MN)
  • Table 12 Global Non-Pharmacologic Modulators Market Outlook, By Hormonal Modulation (2024-2032) ($MN)
  • Table 13 Global Non-Pharmacologic Modulators Market Outlook, By Immune System Modulation (2024-2032) ($MN)
  • Table 14 Global Non-Pharmacologic Modulators Market Outlook, By Pain Pathway Interruption (2024-2032) ($MN)
  • Table 15 Global Non-Pharmacologic Modulators Market Outlook, By Other Mechanisms (2024-2032) ($MN)
  • Table 16 Global Non-Pharmacologic Modulators Market Outlook, By Delivery Mode (2024-2032) ($MN)
  • Table 17 Global Non-Pharmacologic Modulators Market Outlook, By In-Person Therapy (2024-2032) ($MN)
  • Table 18 Global Non-Pharmacologic Modulators Market Outlook, By Digital Therapeutics (2024-2032) ($MN)
  • Table 19 Global Non-Pharmacologic Modulators Market Outlook, By Wearable Devices (2024-2032) ($MN)
  • Table 20 Global Non-Pharmacologic Modulators Market Outlook, By Remote Monitoring Platforms (2024-2032) ($MN)
  • Table 21 Global Non-Pharmacologic Modulators Market Outlook, By Other Delivery Modes (2024-2032) ($MN)
  • Table 22 Global Non-Pharmacologic Modulators Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 23 Global Non-Pharmacologic Modulators Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 24 Global Non-Pharmacologic Modulators Market Outlook, By Distributors (2024-2032) ($MN)
  • Table 25 Global Non-Pharmacologic Modulators Market Outlook, By Online Platforms (2024-2032) ($MN)
  • Table 26 Global Non-Pharmacologic Modulators Market Outlook, By Other Channels (2024-2032) ($MN)
  • Table 27 Global Non-Pharmacologic Modulators Market Outlook, By Application (2024-2032) ($MN)
  • Table 28 Global Non-Pharmacologic Modulators Market Outlook, By Chronic Pain Management (2024-2032) ($MN)
  • Table 29 Global Non-Pharmacologic Modulators Market Outlook, By Mental Health Disorders (2024-2032) ($MN)
  • Table 30 Global Non-Pharmacologic Modulators Market Outlook, By Neurological Rehabilitation (2024-2032) ($MN)
  • Table 31 Global Non-Pharmacologic Modulators Market Outlook, By Sleep Disorders (2024-2032) ($MN)
  • Table 32 Global Non-Pharmacologic Modulators Market Outlook, By Cardiovascular Regulation (2024-2032) ($MN)
  • Table 33 Global Non-Pharmacologic Modulators Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 34 Global Non-Pharmacologic Modulators Market Outlook, By End User (2024-2032) ($MN)
  • Table 35 Global Non-Pharmacologic Modulators Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 36 Global Non-Pharmacologic Modulators Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 37 Global Non-Pharmacologic Modulators Market Outlook, By Rehabilitation Centers (2024-2032) ($MN)
  • Table 38 Global Non-Pharmacologic Modulators Market Outlook, By Homecare Settings (2024-2032) ($MN)
  • Table 39 Global Non-Pharmacologic Modulators Market Outlook, By Academic & Research Institutes (2024-2032) ($MN)
  • Table 40 Global Non-Pharmacologic Modulators Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.